Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Insmed Incorporated - Common Stock
(NQ:
INSM
)
206.78
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Insmed Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind
↗
August 26, 2025
The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.
Via
Stocktwits
Topics
Earnings
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
↗
August 21, 2025
Via
Benzinga
Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
↗
August 21, 2025
Via
Benzinga
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
↗
August 20, 2025
Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035
Via
Benzinga
Intel, UnitedHealth, And Reddit Are Among Top Large Cap Gainers Last Week (August 11-August 15): Are The Others In Your Portfolio?
↗
August 17, 2025
These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.
Via
Benzinga
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease
↗
August 12, 2025
Via
Stocktwits
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
August 14, 2025
Via
Benzinga
Assessing Insmed: Insights From 20 Financial Analysts
↗
August 13, 2025
Via
Benzinga
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
↗
August 13, 2025
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.
Via
Stocktwits
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
August 13, 2025
Via
Benzinga
What Does the Market Think About Insmed?
↗
June 19, 2025
Via
Benzinga
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
↗
August 13, 2025
Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.
Via
Stocktwits
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
↗
August 12, 2025
The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients.
Via
Benzinga
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
↗
August 12, 2025
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.
Via
Investor's Business Daily
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
↗
August 07, 2025
Via
Benzinga
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
August 04, 2025
Via
Investor Brand Network
Topics
Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
August 04, 2025
EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Government
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
↗
July 24, 2025
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.
Via
Investor's Business Daily
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'
↗
July 10, 2025
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for...
Via
Benzinga
Topics
Artificial Intelligence
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts
↗
July 08, 2025
Via
Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
↗
July 02, 2025
Via
Benzinga
Russell Rebalance: 3 Stocks Ready to Move Higher
June 20, 2025
The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000
Via
MarketBeat
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?
↗
June 15, 2025
Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them?
Via
Benzinga
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
↗
June 11, 2025
Via
Benzinga
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
↗
June 11, 2025
BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.
Via
Benzinga
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
June 11, 2025
Via
Benzinga
Deep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings)
↗
June 10, 2025
Via
Benzinga
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
↗
June 10, 2025
Via
Benzinga
Topics
Stocks
10 Health Care Stocks Whale Activity In Today's Session
↗
June 10, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today